By Wayne Koberstein, Executive Editor
Protagonist Therapeutics has created a technology for making stable oral peptides capable of replacing injectable-only drugs, and is developing entirely new oral-peptide therapeutics for GI patients. Its initial development areas are irritable bowel diseases (IBD) and irritable bowel syndrome (IBS). Two compounds, one an injectable peptide to block IL-6, and another an oral peptide to block integrins, will enter clinical trials in 2015.
By Peter J. Brescia, Applications Scientist, BioTek Instruments, Inc.
Here we demonstrate the use of a fluorescent polarization assay using SET7/9, a SET domain containing mono-methyltransferase, as a model system suitable for HTS applications in a 384-well microplate format using automated methods and a HTS microplate reader.
By Mark C. Arjona, Catherine Nguyen, Jenny Y. Bang, Tom Fletcher, and Jessie H.T. Ni
In the production of biologics, various development activities require different medium requirements, calling for multiple media.
By KR Karu, Pharmaceutical Industry Solution Director, Sparta Systems
Supply chain integrity is necessary to a pharmaceutical company’s success. When dealing with a multitude of suppliers spanning several geographies, manufacturing issues can arise if proper protocols are not in place. Specific challenges include product purity, regulatory compliance, safety, cost containment, and quality assurance.
By Stacey Willard, Linette Philip, and Ma Sha
Oxygen is a critical regulator of cellular homeostasis, and as such, oxygen deprivation is lethal to normal cells. In contrast to normal tissues, solid tumors often have regions of significantly reduced oxygenation due to an inconsistent and disorganized blood supply at the center of the tumor.